drugset / Trial / NCT00443170

A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects

NCT00443170

Phase 1 Completed 90 enrolled GlaxoSmithKline
RandomizedSingle-groupSingle-blindTreatment

Summary

This is a first time in human study to investigate the safety of GSK626616AC given as oral single and repeat doses in healthy subjects. An additional group of subjects will be assessed to determine the effect of several drugs given at the same time as GSK626616.

Timeline

Start
2006-11
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule
Subject Flurbiprofen Small molecule
Subject GSK626616 Unknown Oral
Subject Midazolam Small molecule
Subject Omeprazole Other / unclassified
Subject Rosiglitazone Small molecule

Indications